Trials / Completed
CompletedNCT01181427
Study of ABT-267 in Both Healthy Volunteers and Hepatitis C Virus (HCV) Genotype 1 Infected Subjects
A Blinded, Randomized, Placebo-Controlled Study in Healthy and HCV Genotype 1-infected Adults, to Evaluate the Safety, Tolerability, Antiviral Activity, Pharmacokinetics (Including the Effect of Food) and Resistance Profile of Single and Multiple Doses of ABT-267
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 137 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Study of ABT-267 in both healthy volunteers and Hepatitis C virus (HCV) genotype 1 infected subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-267 | See arm description |
| DRUG | Placebo | See arms description |
| PROCEDURE | Blood Sample Collection | See arm description |
| DRUG | Cytochrome P450 inhibitor | See arm description |
Timeline
- Start date
- 2010-08-01
- Primary completion
- 2011-03-01
- Completion
- 2012-01-01
- First posted
- 2010-08-13
- Last updated
- 2012-01-24
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01181427. Inclusion in this directory is not an endorsement.